



AKCI 2017
Affordable Cancer Care in INDIA

Saturday, 18 November, Hotel Taj Palace, New Delhi



about ACCI

As you are possibly aware, 2.5 million Indians are living with cancer while you read this letter. More than 7 lakh new cases register every year, out of which more than 5.5 lakh die of this disease. Recording data is a fairly recent phenomenon in our country, we are recording just the tip of the iceberg. GLOBOCAN predicts record numbers by 2020 - a true 'Cancer Epidemic (NICPR)' in the making. Individual financial cancer burden in India estimated at INR 36,812 at a tertiary public hospital (AIIMS) was approximately 1/10th of that at a tertiary private hospital in 2012. This figure has multiplied 100 fold by now. While a plethora of challenges like Prevention and Early Detection, Inadequate and eccentrically distributed technical and human resource infrastructure stand in the way of our evolution, Inadequate financial resource is perhaps the Core factor at the national, state and individual levels which limits adequate access to standard cancer care in our country.

'BCPBF - the Cancer Foundation' in pursuance of its charter as an advocate of enhanced appropriate, affordable cancer care in India proposed to hold a deliberatory and recommendatory event - **'AFFORDABLE CANCER CARE IN INDIA 2017'** at Hotel Taj Palace, New Delhi on 18 November 2017.

This exercise endeavored to bring Policy makers in India:

Ministry of Health, Ministry of Finance, Ministry of Biotechnology, State Health Ministries, Niti Aayog, ICMR (Indian Council of Medical Research), NICPR (National Institute of Cancer Prevention & Research), NPPA (National Pharmaceutical Pricing Authority), DCGI (Drug Controller General of India), MCI (Medical Council of India), FICCI, CII together with various stakeholders comprising:

OPPI (Organisation of Pharmaceutical Producers of India), IDMA (Indian Drug Manufacturers' Association), Biotech Industry Molecular Diagnostic Industry, Technical Infrastructure corporates like Radiation Equipment Manufacturers, Innovators, Proprietors and Management of Tertiary Care & stand alone Cancer Hospitals, Oncology Opinion Makers, Insurance & Banking industry, Print and Electronic Media, Consumer Patient Advocates, Regulators.

The following topics were discussed threadbare

1. Patent rights for Health Care Products in India - Do they require tweaking?
2. Orphan Drugs and their relevance in Cancer Care India.
3. Biosimilars in Oncology – the way forward in India.
4. Taxation for Oncology products in India needs revisiting.
5. Pricing for Cancer Care in India - Practicality & Affordability.
6. Health Insurance for Cancer Treatment - products available, evolution.
7. Improving Access to Cancer Diagnostics: Entrepreneurial Strategies
8. Impetus to Research & Development in India.
9. Government Policies in Affordable Cancer Care: "Past, Present and Future – a 20 year overview"
10. Enabling effective tertiary healthcare system in India – A much needed reform
11. Family Ecosystem in cancer care

Experts drawn from above fields delivered lectures, indulged in meaningful discussions and contributed towards policy making in India.

It is considerably satisfying to note a response from Health Minister, Govt. of India, in terms of incorporating some of the recommendations towards "Ayushman Bharat".

A welcome step indeed towards Universal Health Coverage.

DR SAMEER KAUL

Organizing Chairman, 'ACCI 2017'

about bcpbf

Cancer is a major threat worldwide; we in India are not immune. Like the rest of the world, it continues to be the second leading cause of mortality. The number of people diagnosed with cancer was 9,79,786 in 2010. The prevalence of cancer is established to be over 3 million in India, with more than 5,50,000 deaths every year. Support groups are doing a yeoman's service in trying to increase awareness and provide education and counseling. Our treatment centers are inundated and professionals grappling to provide optimal care. But the harsh reality is, that despite these facilities, a number of patients have no access to world-class treatment.

Science tries to keep abreast of infirmity. Global efforts towards research, technological advances, financial availability and concern for the afflicted, exhibit heterogeneity. The crux of the problem remains inadequate finances for developing multi modality treatment of acceptable standards and protocols.

This is what motivated a small group of professionals, patients and corporates to act, rather than just discuss the problem and set up **BREAST CANCER PATIENTS BENEFIT FOUNDATION (BCPBF)**

Founded by Dr. Sameer Kaul in September 2004, the BCPBF is an equal opportunity support organization which, in the interim, comprises of well-known medical professionals, financial experts, entrepreneurs, gutsy survivors and philanthropic members of the community. Its sole purpose is to financially benefit those who cannot afford the treatment and to increase knowledge among those unaware of the disease, by reaching out to them through its programmes like 'Knowledge at your doorstep' awareness camps, public lectures, seminars, corporate health checks and other such events. The foundation also aims to motivate the affluent strata of society to contribute towards the noble cause at fund raising events.

PRIMARY OBJECTS & AIMS OF THE SOCIETY ARE:

To subsidize the mammoth cost of treatment of cancer of needy and poor patients and raise funds for the same.

To help early detection of cancer and to raise funds for the said purpose.

To set up detection centers, hospitals, nuclear science and pathological labs and radiation/ chemotherapy centers in rural and urban areas for treatment of cancer patients and raise funds for the same

To convince pharmaceutical companies to provide drugs for cancer treatment at concession rate/free of charge for poor and needy patients

MRIDULARORA

Executive Director, 'BCPBF - The Cancer Foundation'

Panel Consensus



PROGRAMME

8:00 – 8:30 REGISTRATION

8:30 WELCOME ADDRESS **DR SAMEER KAUL**
President, BCPBF the Cancer Foundation, New Delhi

8:45 KEYNOTE ADDRESS **HON'BLE JUSTICE MS PRATHIBA M SINGH**
Judge, Delhi High Court, New Delhi

9:00 – 10:15 SESSION 1 AFFORDABLE CANCER CARE - CURRENT STATUS ?

AFFORDABLE CANCER CARE FOR INDIANS - A POLICY MAKER'S INSIGHT
SPEAKER **MR SUDHANSHU PANDEY**
Joint Secretary, Department of Commerce, Ministry of Commerce & Industry, Govt. of India

AFFORDABLE CANCER CARE - AN ONCOLOGIST'S PERSPECTIVE
SPEAKER **DR SAMEER KAUL**
Sr. Consultant Surgical Oncology & Robotics, Apollo Cancer Institute, New Delhi

PANEL DISCUSSION

CHAIRPERSON **SHRI SUDHANSH PANT**
Joint Secretary (Policy), Dept. of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Govt. of India

MODERATOR **PROF (DR) G K RATH**
Chief, DR BRAIRCH, Prof, Radiation Oncology, AIIMS, N. Delhi

PANELIST **PROF (DR) VINOD K PAUL**
Member, Niti Aayog, Govt. of India

PANELIST **MR DEEPAK BAGLA**
CEO, Invest India, New Delhi

PANELIST **DR G N SINGH**
Drug Controller General of India, Ministry of Health & Family Welfare, Govt. of India

PANELIST **MR BHAGOJI T KHANAPURE**
Drug Controller, DCD, Govt. of Karnataka, Bengaluru

PANELIST **DR ANIL KUKREJA**
Medical Director, Roche Pharmaceuticals, Mumbai

PANELIST **MR HARINDER S SIKKA**
Group Director - Strategic Business, Piramal Enterprises

PANELIST **MR MANISH BAJAJ**
Vice President-Strategy, Portfolio Management & Innovation, Dr. Reddy's Global Generics India

10:15–10:30 INAUGURATION

CHIEF GUEST **SHRI JAGAT PRAKASH NADDA**
Hon'ble Union Minister of Health & Family Welfare, Government of India

GUEST OF HONOR **SMT ANUPRIYA PATEL**
Minister of State, Ministry of Health & Family Welfare, Government of India

10:30–11:45 SESSION 2 INDUSTRY CONCERNS AND REMEDIES

ORPHAN DRUGS AND THEIR RELEVANCE IN CANCER CARE INDIA
SPEAKER **MR AMITABH DUBE**
Business Unit Head, Novartis India Ltd, Mumbai

BIOSIMILARS IN ONCOLOGY – JUST THE RIGHT WAY FORWARD
SPEAKER **DR RAVISHANKAR**
Asst. General Manager, Medical Affairs, Mylan Pharmaceuticals Pvt. Ltd., Bengaluru

TAXATION FOR ONCOLOGY PRODUCTS IN INDIA NEEDS REVISITING
SPEAKER **MR V. LAKSHMI KUMARAN**
Founder and Managing Partner, Lakshmikumaran & Sridharan, New Delhi

PANEL DISCUSSION

CHAIRPERSON **DR RANJEET SHAHANI**
Vice Chairman & Managing Director, Novartis India Ltd, Mumbai

DR VINOD RAINA
Executive Director, Fortis Memorial Research Institute, Gurgaon

MODERATOR **DR ASHOK VAID**
Chairman - Medical & Pediatric Oncology, Medanta - The Medicity, Gurgaon

PANELIST **DR J S THAKUR**
Professor of Community Medicine, PGI, Chandigarh

PANELIST **DR JAIDEEP GUPTA**
Managing Director, Indraprastha Apollo Hospitals, New Delhi

PANELIST **DR SAUMIL MODY**
Vice President - Commercial Operations, Eisai Pharmaceuticals India Pvt. Ltd., Mumbai

PANELIST **MR RAKESH BAMZAI**
CEO, MD, President (India & Emerging Markets), Mylan Laboratories Ltd., Bengaluru

- PANELIST **DR ROHIT V NAYYAR**
Director, Asian Cancer Centre, Asian Institute of Medical Sciences, Faridabad
- PANELIST **DR (MAJ GEN) S C PAREEK**
Director, Bhagwan Mahaveer Cancer Hospital & Research Centre, Jaipur
- PANELIST **DR SANJIT SINGH LAMBA**
Managing Director, Eisai Pharmaceuticals India Pvt Ltd

11:45 – 1:00 **SESSION 3** **INDIGENOUS RESEARCH & DEVELOPMENT**

- IMPETUS TO RESEARCH & DEVELOPMENT IN INDIA IS WANTING**
- SPEAKER **DR SHYAM AGARWAL**
Chairman Oncology, Sir Ganga Ram Hospital, New Delhi
- A PUBLIC PRIVATE PARTICIPATION FOR CANCER PREVENTION**
- SPEAKER **DR SWATI A PIRAMAL**
Vice Chairperson, Piramal Enterprises Ltd., Mumbai
- CHALLENGES & OPPORTUNITIES IN RESEARCH FOR AFFORDABLE CANCER CARE IN INDIA**
- SPEAKER **DR JITENDAR K SHARMA**
Advisor (Health), Govt. of Andhra Pradesh & MD & CEO - AMTZ, Visakhapatnam

- PANEL DISCUSSION**
- CHAIRPERSON **MR HEMANT BATRA**
Director, The Batra Group, New Delhi
- MODERATOR **DR DEEPAI KAPOOR**
Onco-Psychologist, Apollo Cancer Institute, New Delhi
- PANELIST **DR B S SRINATH**
Sr Consultant Surgical Oncology, Sri Shankara Cancer Foundation, Bengaluru
- PANELIST **MR DAVINDER SINGH BRAR**
Chairman, GVK Biosciences Pvt. Ltd., New Delhi
- PANELIST **MR MANOJ PANANCHUKUNNATH**
Head of Global Injectables, Scientific Affairs, Mylan Laboratories Ltd, Bengaluru
- PANELIST **DR RAJAT GOYAL**
Country Director - India, International AIDS Vaccine Initiative, New Delhi
- PANELIST **DR SHEKHAR SALKAR**
Sr. Consultant Surgical Oncology, Manipal Hospital, Goa
- PANELIST **MR SURESH RAMU**
Co-Founder & CEO, Cytecure Hospitals, Bengaluru
- PANELIST **DR THOMAS VARUGHESE**
Director Cancer Division, Surgical Oncology & Reconstructive Surgery, Renai Medicity Hospital, Cochin

02:00 – 3:15 **SESSION 4** **EARLY STANDARD CURRENT DIAGNOSTICS**

- CANCER DIAGNOSTICS – CURRENT STATUS AND AFFORDABILITY**
- SPEAKER **DR NITESH ROHATGI**
Sr. Consultant Medical Oncology, Max Healthcare, New Delhi
- AFFORDABLE EARLY DIAGNOSIS – A CHALLENGE FOR GOVERNMENT**
- SPEAKER **DR RAVI MEHROTRA**
Director, National Institute of Cancer Prevention & Research, Govt. of India, New Delhi
- IMPROVING ACCESS TO CANCER DIAGNOSTICS: ENTREPRENEURIAL STRATEGIES**
- SPEAKER **MS ZOYA BRAR**
Founder & Managing Director, Core Diagnostics, New Delhi

- PANEL DISCUSSION**
- CHAIRPERSON **PROF (DR) R.K. VYAS**
Prof & HOD, Radiation Oncology & Director, Gujarat Cancer & Research Institute, Gujarat
- MODERATOR **DR HARSH MAHAJAN**
Founder & Chief Radiologist, Mahajan Imaging, New Delhi
- PANELIST **DR JAGDEV SEKHON**
Director Oncology, Fortis Hospital, Ludhiana, Punjab
- PANELIST **DR K GOVIND BABU**
Professor of Medical Oncology, Kidwai Memorial Institute of Oncology, HCG Hospitals, Bengaluru
- PANELIST **DR REENA NAIR**
Sr. Consultant, Clinical Haematology, Tata Medical Centre, Kolkata
- PANELIST **DR SANJEEV MISRA**
Director & CEO, All India Institute of Medical Sciences, Jodhpur
- PANELIST **MR SATISH DESHPANDE**
Strategy Consultant, Datar Genetics Limited
- PANELIST **DR SHANKAR SRINAVASAN**
Consultant Medical Oncology, Apollo Speciality Cancer Hospital, Chennai
- PANELIST **DR MANJIRI BAKRE**
Founder and CEO, OncoStem Diagnostics Pvt. Ltd., Bengaluru

03:15 – 4:45 SESSION 5 PATIENT EDUCATION, ADVOCACY GROUPS & ROLE OF MEDIA

- SPEAKER** **PATENT RIGHTS FOR HEALTH CARE PRODUCTS IN INDIA**
MR PRAVIN ANAND
Managing Partner, Anand & Anand, New Delhi
- SPEAKER** **FAMILY ECOSYSTEM IN CANCER CARE**
DR Y K SAPRU
Founder Chairman & CEO, CPAA, Mumbai
- SPEAKER** **VALUE BASED CANCER CARE IN INDIA**
DR B S AJAI KUMAR
Chairman & CEO, HealthCare Global Enterprises Limited, Bengaluru
- SPEAKER** **PUBLIC PRIVATE PARTNERSHIPS - TOWARDS BUILDING OPTIMUM AND AFFORDABLE CANCER CARE**
MS FRANCES MILNES
Head, Market Access, Emerging Growth Markets, Novartis, USA

PANEL DISCUSSION

- CHAIRPERSON** **PROF (DR) K S GOPINATH**
Director & Surgical Oncologist, HCG, Bangalore Institute of Oncology, Ambuja Health Care, Bengaluru
- MODERATOR** **MS SANCHITA SHARMA**
Sr. Health Editor, Hindustan Times, New Delhi
- PANELIST** **DR JAGDISH PRASAD**
Director General of Health Services, Ministry of Health & Family Welfare, Govt. of India
- PANELIST** **DR H G KOSHIA**
Commissioner, Food & Drug Control Administration, Gujarat
- PANELIST** **DR CHANCHAL GOSWAMI**
Sr. Consultant Medical Oncologist, Medica Superspeciality Hospital & AMRI Hospitals, Kolkata
- PANELIST** **MR SAUMIL MODY**
Vice President - Commercial Operations, Eisai Pharmaceuticals India Pvt. Ltd., Mumbai
- PANELIST** **DR S HUKKU**
Sr. Consultant & Chairman, Radiation Oncology, BLK Super Speciality Hospital, New Delhi
- PANELIST** **DR SANAULLAH KUCHAY**
Professor & Head, Dept. of Radiation Oncology, GMC, Srinagar, J&K
- PANELIST** **DR Y INDIBOR SINGH**
Professor, Dept. of Radiation Oncology, Regional Institute of Medical Sciences, Imphal

5:00 – 6:15 SESSION 6 THERAPY PRICING, INSURANCE & COPAY

- SPEAKER** **PRICING FOR CANCER CARE IN INDIA - PRACTICALITY & AFFORDABILITY**
MR BHUPENDRA SINGH
Chairman, National Pharmaceutical Pricing Authority, Govt. of India
- SPEAKER** **HEALTH INSURANCE FOR CANCER TREATMENT - PRODUCTS AVAILABLE, EVOLUTION**
MS SHOBHANA KAMINENI
President, CII, New Delhi
- SPEAKER** **GOVERNMENT POLICIES IN AFFORDABLE CANCER CARE: "PRESENT & FUTURE – A 20 YEAR OVERVIEW"**
MR AMITABH KANT
CEO, Niti Aayog, New Delhi

PANEL DISCUSSION

- CHAIRPERSON** **DR S H ADVANI**
Director of Medical Oncology, Haematology, Jaslok Hospital & Medical Research Institute, Mumbai
- MODERATOR** **MS FATIMA MAHDI KARAN**
Consulting Editor, BTVI, New Delhi
- PANELIST** **DR SUDHIR GUPTA**
Additional Deputy Director General, Ministry of Health & Family Welfare, Govt. of India
- PANELIST** **MR NAVDEEP RINWA**
Joint Secretary, Ministry of Health & Family Welfare, Govt. of India
- PANELIST** **DR ASHUTOSH GUPTA**
Sr. Consultant Radiation Oncology, Department of Radiotherapy, Medical College, Jammu
- PANELIST** **DR AJAY BAPNA**
Sr. Consultant & HOD, Medical Oncology, Bhagwan Mahaveer Cancer Hospital & Research Centre
- PANELIST** **DR RAKESH CHOPRA**
Sr. Director, Paras Hospitals, Professor of Medicine, UNMC, Omaha, Nebraska
- PANELIST** **DR ULLAS BATRA**
Consultant Medical Oncology, Rajeev Gandhi Cancer Institute & Research Centre, New Delhi

6:15 – 6:45 RECOMMENDATIONS - ACCI 2017



PANEL 1

AFFORDABLE CANCER CARE - CURRENT STATUS ?

Political will to brainstorm, strategize, implement, audit as a coordinated exercise over a defined period of time.

Bundled payment system for health care providers.

Health Payers to be encouraged to adopt innovative value-based systems like 'Payment for clinically meaningful outcomes'.

Public - Private and Private - Private partnerships for early detection strategies.

Increased reimbursement for indigenous, innovatory research careers.

Govt. should adopt complete cancer health care for below poverty line patients across the country.

Every oncology clinician to keep mind space for value while dealing individually.

Encourage evidence-based protocols for cancer management to plug waste.

Tobacco exposure to general populations to be reduced through various measures. Consider executing ban.

Private insurance sector to be stimulated to fully include cancer in their policies.

Adopt measures to decrease the oncology care provider – patient ratio.



PANEL 2

INDUSTRY CONCERNS AND REMEDIES

The reduction of taxes under GST Regime for identified cancer treatment and diagnostic medical devices for domestic and domestically operating international companies, high technology and high value oncological bio pharma products, specialized cancer service delivery.

Imposition of tobacco and associated product cess and allocation of the same for tackling NCD's including cancer in India.

International & National health care Industry be incentivized to manufacture, assemble, package in India under 'Make in India' program of Govt. of India.

Enact Orphan Drugs Act in India to stimulate administrative, research and economic activity in this area for oncology products (drugs, radiation, surgery).

Price capping unilaterally be not overdone for it is certain to blunt innovation in this country and is a short term, single numbered measure.

Biosimilar research licensing and manufacturing be incentivized in India.

Increase budgeting allocation for cancer awareness, high risk screening, mass vaccination for HPV, Hep B in target population.

Ensure participation from private sector in Expert Committee's of DCGI.

Encourage Health Payers (Central & State Govt. of India), Insurance Companies, to pay for clinically meaningful outcomes in cancer treatment.

Biopharma & Medical Device Industry to consider tiered pricing, and other measures to enhance access to advanced cancer care.

More medium and small range oncology services from large hospitals / centers of excellence to smaller community-based hospitals.

Public - private participation models to be explored actively for preventive programs, creation of technical infrastructure for diagnostics and treatment.

Prioritize training of human resource at all levels in oncology.



PANEL 3

INDIGENOUS RESEARCH & DEVELOPMENT

Manufacture and assemble all equipment in India, under 'Make in India' to reduce cost.

Ban or reduce consumption of tobacco and its products.

Incentivize Indian origin scientists to come back to India to increase indigenous research.

Industry-academia collaboration for better paying research jobs and opportunities to increase number of young scientists.

Government teaching institutions can help in training specialist doctors, researching new methods and treatment as this may be subsidized.

Use indigenous organic natural resources to use in cancer care and research. Stimulate interaction with AYUSH.

Develop pre-clinical studies to find alternative means to treat cancer.

Govt must map out cancer treatment facilities available and give grants to the states, provided the states start projects in areas where no treatment is available in both private as well as govt sector. This is important as it is futile to start a cancer facility in same area duplicating huge investment just because the govt is giving 120 cr. In such areas govt can be purchaser of facility rather than spending money on infrastructure.

All centers developed with grants from govt must buy 'Make in India' linac machine and other locally manufactured medical instruments as far as possible.

Stop interfering in pvt. sector like Karnataka government unless hospital takes major grants from govt.



PANEL 4

EARLY STANDARD CURRENT DIAGNOSTICS

R&D for manufacturing and developing scanning and imaging equipment in India under “Make in India”. This will ensure reduced cost of diagnosing and imaging cancer.

Bringing any machine part by part is cheaper than bringing in the whole machine. Assembling equipment in India can help reduce costs while manufacturing isn't happening in India.

Quality of life of patient should not be compromised in the face of cutting costs.

Strict guidelines and protocols should be formed for patient care and follow up to eliminate unwanted and unnecessary tests and scans.

Govt. should increase funds and grants allocated to cancer detection.

Cancer screening at primary health center level for oral, breast and cervical cancer should be mandatory by the government.

Cancer screening and awareness camps can help with early detection and prevention. These can be effective under public-private partnerships.

Resource utilization - Imaging and diagnostic tests can be subsidized in cancer centers after a certain point in day.

If cancer screening is made mandatory every half yearly is made mandatory by the government and private sector for all its employees, early detection of cancer will become fairly widespread.

Access to cancer diagnosing equipment can be made easier by an Uber-like service which can show the nearest cancer centers and book an appointment. This will require the government to partner with companies like Apple, Google, and others.



PANEL 5

PATIENT EDUCATION, ADVOCACY GROUPS & ROLE OF MEDIA

Widespread screening for oral, breast and cervical cancer.

Educate for prevention of lung cancer.

20 cancer hospitals to be made in each state (proposal already approved by the government)

Pharmaceuticals to supply drugs directly to hospitals at cost price. Remove middlemen. This can significantly reduce the price of cancer therapy.

State government should adopt and implement guidelines created by the central government to do away with unnecessary testing & treatment.

Private institutes should invest more in screening and preventive care.

Government monitors drugs with more stringent regulations.

- a. Mindset regarding cancer care must change.
- b. Cost can be reduced with better pain management and lesser referrals.

Telemedicine can eliminate time wastage and cost of travel.

- a. To retain good medical personnel, good infrastructure and incentives must be provided.

Media must accept responsibility of spreading cancer awareness through the masses. Guidelines must be created by the press council for media to cover healthcare.



PANEL 6

THERAPY PRICING, INSURANCE & COPAY

Generalized care for different strata of the society.

The rich should donate more to subsidize cancer care costs for everyone else.

Mental health personnel are required for effective affordable care.

Miscellaneous costs (travel, nutrition etc.) must also be kept in mind along with cost of investigations and treatment. Drugs only make up 45% of cancer care cost.

Cost of investigations and treatment should be reduced or regulated.

Insurance coverage should be more comprehensive to provide better care.

Price capping can work at reducing cost of drugs.

State can co-pay for better cancer care for patients who cannot afford it.

Drugs can be divided into 2 categories:

- i. Essential - price controlled by the government.
- ii. Desirable - optional treatment for those who can afford it.

Insurance to be made compulsory for all.

Recommendations:



INVEST INDIA

NATIONAL INVESTMENT PROMOTION AND
FACILITATION AGENCY

Respected Industry, Govt. Stakeholders,

We thank you for your time and suggestions at the roundtable on "Affordable Cancer Care" hosted by 'BCPBF - The Cancer Foundation' on November 18th, 2017. Please find below minutes of discussions.

As next steps, we would request you to help us substantiate these points with specific examples/benchmarks, successful case studies and detailed explanations. This would help us build the case within relevant departments to make suitable policy amendments. Once we hear back from the group, we will then start mapping out nodal officers and draft a white paper to act as roadmap for affordable cancer care.

INVEST INDIA RECOMMENDATIONS

AWARENESS

1. Govt. spending on awareness campaigns and need for screening, primary care should be scaled up
2. Push towards tobacco ban, (track outcome of measures taken)

PRIMARY HEALTHCARE/ SCREENING

3. Screening for Non communicable diseases under PPP mode (pilot runs)
4. Community based approach (Eg. Piramal foundation)

INFRASTRUCTURE & CAPACITIES

5. One major cancer centre in every 250 km diameter with govt grants of 120 cr
6. One smaller centre with 50 cr grant within 100 km area
7. Give training to all district hospital in chemotherapy handling and regular surgical procedure and post operative care

DATA FOCUS

8. Patient outcome should be studied for treatments given
9. E-health records to collected to analyse meaningful insights
10. Cohort studies & clinical data for better outcomes (customised for Indian patients)

FUNDS

11. Corporate CSR Funds (to be encouraged also for NCDs)
12. Total Grants to be given for cancer research
13. Funds to be made available with lower interest rates for critical diseases research and cure
14. Taxes and recoveries from sale of tobacco to be directed towards cancer care

SOCIAL SECURITY

15. Social security (tiered fashion covering all sub-groups BPL,APL)
16. Andhra Pradesh/ Karnataka / Goa Insurance Models case studies – high population coverage
17. Insurance coverage should not exclude diseases rather coverage base to be increased

RESEARCH

18. Reimbursements for research
19. Weighted tax deduction to be restored at 200%
20. More incubation centres with in academic institutions and hospitals should be proposed
21. Point of Care technology development should be encouraged
22. Now that CDSCO has devised Good clinical Practice guidelines, clinical trials should be scaled up (in a controlled environment to avoid malpractices but promote research)

LICENCES , IMPLEMENTATION

- 23. Better coordination between Centre & State FDAs (CDSCO + State FDAs)
- 24. Licenses for opening hospitals should be rationalised (~80 licenses)
- 25. Stricter Quality control for generics (Develop Indian standards)
- 26. Push for quality generics

IMPORT TARIFFS



- 27. High custom duties- pain point (Balanced approach, raising tariffs in phased manner – based on data - starting with self-sufficient equipment and tech)


PUBLIC PROCUREMENT

- 28. Govt. to be a purchaser of indigenous output
- 27. Preferential market access - localisation norms to be relaxed to 25% for cancer care technology

BROWNFIELD INVESTMENTS – FDI RULES

- 28. Core R&D to be mandated under brownfield route
- 29. Push for more investments in the field of Radiation oncology equipment







HON'BLE JUSTICE Ms PRATHIBA M. SINGH

Judge, Delhi High Court, New Delhi

ACCI 2017 - A great effort !
I look forward to the day
when AFFORDABLE CANCER CARE
becomes AFFORDABLE CANCER CURS.

- PRATHIBA M. SINGH - JUDGE,
DELHI HIGH COURT.

18.11.17.



HON'BLE Smt Anupriya Patel

Minister of State, Ministry of Health & Family Welfare, Government of India



Anupriya Patel
@AnupriyaPatel

Following

Attended @ACCI_2017 Conference on "Affordable Cancer Care in India" today. Our Government is sincerely working on [#CancerCare](#). Recently [@MoHFW_INDIA](#) approved a scheme for enhancing the Tertiary Care Cancer Facilities in the country under NPCDCS.



Dr SUDHIR GUPTA
Additional Deputy Director General
Ministry of Health & Family Welfare
Government of INDIA



*Early detection leads to effective cure
Let's ensure it with affordable Cancer Care*

Sudhir Gupta






Mr SUDHANSHU PANDEY

Joint Secretary, Department of Commerce,
Ministry of Commerce & Industry
Government of INDIA

I am extremely glad to be part of ACCI family for a cause which is very close to my heart. As the human society has progressed, underwent lifestyle changes and changes in food habits, cancer has also spread its deadly wings. In India ever since launch of National Cancer Control Programme in 1975, we have come a long way but CANCER prevention, control and cure needs a holistic approach to be effective in a poor country like India where large population is still not fully covered by insurance and don't have access to public health institutions, cost of treatment assumes great significance. Many families go broke and slip into destitution if any one of their loved one gets affected with cancer.

ACCI has successfully brought all stakeholders on one platform to emphasize on the importance of a holistic approach in making cancer care affordable. I wish them every success in their noble endeavour.




Sudhanshu Pandey
Joint Secretary
Min. Comm &
Industry
18/11/17

Mr SUDHANSH PANT

Joint Secretary (Policy), Dept. of Pharmaceuticals
Ministry of Chemicals & Fertilizers
Government of INDIA



ACCI and the seminar being organized by the BCPBF is a programme which will benefit all the stakeholders and most of all the patients. Cancer is still a much dreaded word and to be able to provide affordable cancer care is a huge service to humankind. I applaud this initiative and especially compliment Dr. Kaul and his team for bringing this even together and getting the companies, policy makers, medical professionals and patients on a common platform.

Best wishes for this and all such future endeavours. Thank you for the invitation.

Sudhansh Pant 18/11/2017

Joint Secretary
Department of Pharmaceuticals
Ministry of Chemicals & Fertilizers
Government of India





Dr H.G. KOSHIA

Commissioner, Food & Drug Control Administration,
Gujarat

Affordable Cancer Care in India 2017
Organized by BCPBF is one
of unique type of programme
where they have covered
Policy making, medical decisions,
Education, etc.

It was very good learning &
sharing platform for working
of the Society to make
"Cancer free"

my best wishes to BCPBF
cancer care foundation team



— @Koshia

Dr. H. G. KOSHIA
Commr, FDCI
GUJARAT

Good session conducted.
on 18/11/2017.

Very informative, innovative
sessions and good learning

~~T. Khapure~~

18/11/2017

Bhagoji. T. Khapure -

Dogs controller for
the state of Karnataka
94491-97800

11/2/17

Kudos to Domwaji for organising
a Scientific Enkoyanza, to awaken
the eyes of health care givers & cross society
we need to work in tandem to organise
the need to enhance cancer care to
every individual in India.

Here's wishing You All


The Very Best God Bless

Phere

Dr (Pm) Richard
Chapman

18/11/2017

One of the best day
to learn about pt and
to work and medical profession
together.
All the best


Dr S. H. Adams

Great Initiative
Nice to be associated
S. Mody

A great forum -
very innovative and
a great set of
people.
Really enjoyed it.
Anand

Dear Mridul & Dr. Kaul,

This has been the most
enlightening experience of my
past five years in cancer
management. Please do more
in future

Best,

Patish
00

It was a unique meeting
which I have attended which
focused on affordable cancer
care in India.

Ajay Bagga
(DR. AJAY BAGGA)

A totally different meeting on
Oncology. Loved to attend
at the real core issues
which ought to have been discussed
earlier were discussed.

Ashwath
(Dr. Ashwath)

Good Concepts
Good Beginnings
Wish all success.
Dr. Thomas Varghese

Great place of organization
for this very critical area
for the healthcare community
to focus on!

Dr. Sathish Deshpande

Excellent concept & we all stakeholders
need to contribute in this space
for ITC in India.

Dr. Anil Kumar
Dr. Anil Kumar

Thanks

Te Suk
ICMR-MCPR, N-I

Good meeting. Recommendations should be shared with Govt, MOW and key stakeholders. We on behalf of World NCD Federation, wish all success to meeting and I will be happy to work closely universal access to NCD care and living cancer control

Dr J. S. Indran
(Dr J. S. Indran)
President World NCD Federation


MANISH BAJAJ

Dr. Ajay Bopara


Amitabh Dube

FRANCES MILNES

Dr. Shukla Sathar


Ajay Bopara

Amitabh Dube





Great initiative!

Happy we can see India
back on the world's map.
SUCESA KAN



J. S. Thakur

V. K. Sapat

Dr. Sanjeev Thoria

Dr. Gopinath

Dr. Govind Babu


V. K. Sapat
Sanjeev Thoria

Let's Continue the
good work



May the initiative help and
bless patients!

Divine


Payal Kaul,

Great to be associated
with the cause.

Gurpreet Kaur
Gill
18/11/19

Harpreet
Kaur / Panchan,

Very useful is
conference. Hope is
the recommendations will
be implemented!
Manjit's Bolkie
Oncostem Diagnostics
18/11/2017


Dr. Shubha Salve
2009

Cancer is about - Prevention
Keep fighting & persistence.
Great Initiative
All the very best
Manoj Kumar
Apollo Hospital
Dr. Ravichandkar.

Amman

Chris

Justin

Chris?

Justin

John

John

John

John

John

John

John

John

John

John

John

John

John

John

John

John

John

John

John

Devi
Asanmatta
Des

Sh

Sh

Shukrakkandgal

Kijani Kura:

Sh

Debul ma
Des

Sh

Shyona

Shu Shu

Shu

Indrak Mahay

Prakash Singh

Justina Gaur

Raj
Aradh Jain

Sakya

Dr. Sachin Kumar Gupta

Aditya

Aditya Sidani

Deepika Malhotra

Deepthi Malhotra

Rajni

Prakash
Sinha

Amal

Satish
Savanna

Amal

Vinod Kulkarni

Abhishek

Narinder

MALTI KACHSEV

Amal

Naz

Cyber
Post
Ar

Amal

[Signature]

Dr. Mahesh Kumar.

[Signature]

Samer Koul.

[Signature]

(Michael Anora)

[Signature]

(ANJALI KANWAR)

[Signature]

Naveen

[Signature]

(SUMEET NAIR)

Atkarsha Agnihotri

[Signature]



ORDABLE CANCER CARE IN INDIA



BCPBF - THE CANCER FOUNDATION

A-1/132 L.G.F. | Safdarjung Enclave | New Delhi 110029
09811061709 | bcpbf@hotmail.com | www.bcpbf.com



BCPBF.Cancer



BCPBF_2018